Trial · NCT07218029
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
NCT07218029, Phase 3, Active not recruiting, Merck Sharp & Dohme LLC
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038). Trials, record NCT07218029. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07218029
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
- NCT number
- NCT07218029
- Status
- Active not recruiting
- Phases
- Phase 3
- Enrollment
- 815 participants, estimated
- Lead sponsor
- Merck Sharp & Dohme LLC
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Sotatercept
- First posted
- 2025-10-20
- Last updated
- 2026-10-08
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Who Experience an Adverse Event (AE) | Up to approximately 90 months | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported. |
| Primary | Number of Participants Who Discontinue Study Treatment Due to an AE | Up to approximately 86 months | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported. |
| Primary | Number of Participants with Detectable Anti-Drug Antibodies (ADAs) | Up to approximately 88 months | ADAs will be detected in serum. The number of participants with detectable ADAs will be reported. |
| Primary | Laboratory parameters (Hematology): Concentration of Platelets and Hemoglobin | Up to approximately 88 months | Blood samples will be collected to determine the concentration of platelets and hemoglobin. |
| Primary | Laboratory parameters (Chemistry): Concentration of Creatinine, Total Bilirubin, and Alanine Aminotransferase (ALT) | Up to approximately 86 months | Blood samples will be collected to determine the concentration of creatinine, total bilirubin, and ALT. |
| Primary | Change From Baseline in Body Weight | Baseline and up to approximately 86 months | Change from baseline in body weight will be reported. |
| Primary | Change From Baseline in Blood Pressure | Baseline and up to approximately 86 months | Change from baseline in systolic and diastolic blood pressure will be reported. |
| Primary | Change From Baseline in Electrocardiogram (ECG) | Baseline and up to approximately 86 months | Change from baseline in ECG (12-lead) for the determination of Fridericia's corrected QT interval (QTcF) will be reported. |
| Secondary | Change From Baseline in 6-Minute Walk Distance (6MWD) | Baseline and up to approximately 48 months | The 6MWD is the distance walked in 6 minutes as a measure of functional capacity. The change from baseline in 6MWD will be reported. |
| Secondary | Change From Baseline in N-Terminal Pro-Hormone B-type Natriuretic Peptide (NT-proBNP) Levels | Baseline and up to approximately 48 months | NT-proBNP is a circulating biomarker that reflects myocardial stretch. The change from baseline in NT-proBNP levels will be reported. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 39978862 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07218029
GET https://conductscience.org/api/trials/v1/NCT07218029/registered